Terzis Georgios
Known title: Chief Financial OfficerCIK: 0001835415
Terzis Georgios's purchase track record
Terzis Georgios has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/16/2026 | COSM | $42K | +11.2% | pending | — |
| 12/20/2024 | COSM | $50K | -16.6% | -25.9% | +0.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| COSM | ▲ Buy | Grant | 328,407 | $60K | 7/29/2026 | View on chart |
| COSM | ▲ Buy | Open Market | 168,135 | $42K | 6/16/2026 | View on chart |
| COSM | ▲ Buy | Grant | 850,000 | $241K | 5/19/2026 | View on chart |
| COSM | ▲ Buy | Open Market | 85,778 | $50K | 12/20/2024 | View on chart |
| COSM | ▲ Buy | Grant | 51,485 | $52K | 10/24/2023 | View on chart |
| COSM | ▲ Buy | Grant | 100,000 | $100 | 4/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cosmos Health Subsidiaries Report Record Revenue Milestones
Cosmos Health reported that its CosmoFarm division reached an annualized revenue run rate above $60 million, a 4.3x increase since acquisition. The company stated that robotics and AI systems are expanding capacity to support over $100 million in future revenue. Additionally, its contract manufacturing and Cana Laboratories divisions surpassed $20 million in implied revenue each.
Cosmos Health Subsidiaries Report Record Revenue Milestones. Cosmos Health reported that its CosmoFarm division reached an annualized revenue run rate above $60 million, a 4.3x increase since acquisition. The company stated that robotics and AI systems are expanding capacity to support over $100 million in future revenue. Additionally, its contract manufacturing and Cana Laboratories divisions surpassed $20 million in implied revenue each.